Why the resistance @ 21? Appears some were burned in the past. Read Rxkell and understand background behind small secondary. We are in the calm before the storm. I'll add a few.
Total shares short is 22,623,319 (45,000,000 outstanding float). Short interest increasing since the panel's decision. 30 may be possible this week??
Jefferies CEO Rich Handler is Tillman Fertitta's right hand man. Very much of a risk taker and worked for Michael Milken's junk bond desk making 100s of millions before starting JEF. They just took over a 100MM loss on junk energy portfolio and many employees have exited. They will need to dump this analyst soon as well.
History shows it's not in the FDA's DNA to go from Negative to Positive so quickly. They must save face. Today they decided to take the first step up to neutral with a positive outlook. The Texas 2 step is coming.
1.6 market cap appears to be low for a tech play with 700MM , growing rev, no debt and 370MM in cash with virtually no debt. Einhorn ain't dumb. Should be well over 25 on these numbers
One reason Cramer may not get the respect he deserves -- you will never hear him say 'this stock is cheap on a valuation basis.' Great investors throughout history have been value investors. When is the last time you have heard him say the two words "market capitalization" or us a market cap based ratio? Never.
If a tech company had a market cap of 1.5B, growing revs and eps, sales of 1.5B, cash of 500MM and no debt he would not think it's a great investment where a value manager might.
As far as the google argument, I disagree. Even using google. searches I seem to be using yelp more and more.
I have a hunch Greenlight will be the winner here. YELP 22
What's more interesting to me is the low 500MM MARKET CAP with 200MM in cash. WOULD A POTENTIAL ACQUIRER BE INTERESTED? YES or NO? P3 too expensive to for big pharma?
Sure they would need cash infusion on the for P3 trial but what a cheap way for a multinational biotech acquire what could be a multi billion dollar drug that appears to work. 12 person study which what is all the panel had to go against. 7-6 vote. FDA commissioner likes it. Could it be cheap here?